• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lobe Sciences Ltd (CSE:LOBE)

    0.0700 UNCHANGED
    Streaming Delayed Price Updated: 9:37 AM EDT, Mar 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 126,450
    Open 0.0750
    Bid (Size) 0.0550 (158,000)
    Ask (Size) 0.0700 (31,000)
    Prev. Close 0.0700
    Today's Range 0.0700 - 0.0750
    52wk Range 0.0200 - 0.1100
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
    Via ACCESS Newswire

    Performance

    YTD
    +40.0%
    +40.0%
    1 Month
    +40.0%
    +40.0%
    3 Month
    +55.6%
    +55.6%
    6 Month
    +40.0%
    +40.0%
    1 Year
    +133.3%
    +133.3%

    More News

    Read More
    News headline image
    Lobe Sciences Reports First Quarter 2026 Results and Highlights
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Completes Debt Settlement to Improve Balance Sheet
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Improves Balance Sheet
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Announces the Closing of the Previously Announced Private Placement
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Ltd. Announces Debt Settlement
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
    Via ACCESS Newswire
    News headline image
    Lobe Sciences Provides Corporate Update
    Via ACCESS Newswire
    News headline image
    Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
    From Lobe Sciences Ltd.
    Via Business Wire
    News headline image
    Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
    From Lobe Sciences, Ltd.
    Via Business Wire
    News headline image
    Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
    From Lobe Sciences, Ltd.
    Via Business Wire
    News headline image
    Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc.
    From Lobe Sciences Ltd
    Via Business Wire
    News headline image
    Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team
    From Lobe Sciences Ltd
    Via Business Wire
    News headline image
    Lobe Sciences Announces Update
    From Lobe Sciences Ltd.
    Via Business Wire
    News headline image
    Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
    From Lobe Sciences Ltd.
    Via Business Wire

    Frequently Asked Questions

    Is Lobe Sciences Ltd publicly traded?
    Yes, Lobe Sciences Ltd is publicly traded.
    What exchange does Lobe Sciences Ltd trade on?
    Lobe Sciences Ltd trades on the Canadian Securities Exchange
    What is the ticker symbol for Lobe Sciences Ltd?
    The ticker symbol for Lobe Sciences Ltd is LOBE on the Canadian Securities Exchange
    What is the current price of Lobe Sciences Ltd?
    The current price of Lobe Sciences Ltd is 0.0700
    When was Lobe Sciences Ltd last traded?
    The last trade of Lobe Sciences Ltd was at 03/16/26 09:37 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.